In June 2019, Eutropics Pharmaceuticals was awarded highly competitive funding from MassVentures’ SBIR Targeted Technologies (START) program to support the commercialization of its PraediCare Dx predictive cancer diagnostics platform. The non‑dilutive START Stage III grant builds on earlier Stage I and II awards and is aimed at accelerating PraediCare Dx’s transition from an NIH/NCI‑funded SBIR technology to a widely adopted clinical and pharma‑facing product. This MassVentures support underwrites critical go‑to‑market activities, including clinical deployment and partnerships with pharmaceutical companies using PraediCare Dx to guide drug development, and underscores the Commonwealth’s confidence in Eutropics’ ability to deliver personalized cancer treatment tools and drive economic growth in Massachusetts
